These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37030091)

  • 1. Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
    Qin Q; Fu Q; Wang X; Lv R; Lu S; Guo Z; Wu T; Sun Y; Sun Y; Liu N; Zhao D; Cheng M
    Eur J Med Chem; 2023 May; 253():115291. PubMed ID: 37030091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
    Qin Q; Guo Z; Lu S; Wang X; Fu Q; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Jan; 264():115953. PubMed ID: 38029466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel indazole derivatives as second-generation TRK inhibitors.
    Qin Q; Lu S; Guo Z; Li Z; Fu Q; Wang X; Wu T; Sun Y; Liu N; Zhang H; Zhao D; Cheng M
    Eur J Med Chem; 2024 Oct; 276():116640. PubMed ID: 39033612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors.
    Xu Y; Zhao W; Zhang X; Yu X; Chen Y; Wang Z; Chu Y; Zhu X; Zhang P
    Bioorg Med Chem; 2024 Feb; 99():117608. PubMed ID: 38271867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.
    Wang Z; Wang J; Wang Y; Xiang S; Zhou H; Song S; Song X; Tu Z; Zhou Y; Ding K; Zhang ZM; Zhang Z; Lu X
    J Med Chem; 2023 Sep; 66(18):12950-12965. PubMed ID: 37676745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.
    El-Nassan HB; Al-Qadhi MA
    Eur J Med Chem; 2023 Oct; 258():115618. PubMed ID: 37413881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.
    Xiang S; Wang J; Huang H; Wang Z; Song X; Zhou Y; Jin F; He X; Zhang ZM; Tu Z; Ding K; Zhang Z; Lu X
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114899. PubMed ID: 36410169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.
    Gong Y; Wu FX; Wang MS; Xu HC; Zhuo LS; Yang GF; Huang W
    Eur J Med Chem; 2022 Nov; 241():114654. PubMed ID: 35961071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo.
    Wang J; Zhou Y; Tang X; Yu X; Wang Y; Chan S; Song X; Tu Z; Zhang Z; Lu X; Zhang Z; Ding K
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
    Wang B; Zhang W; Liu X; Zou F; Wang J; Liu Q; Wang A; Hu Z; Chen Y; Qi S; Jiang Z; Chen C; Hu C; Wang L; Wang W; Liu Q; Liu J
    Eur J Med Chem; 2020 Dec; 207():112744. PubMed ID: 32949955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, biological evaluation and pharmacophore model analysis of novel tetrahydropyrrolo[3,4-c]pyrazol derivatives as potential TRKs inhibitors.
    Wu T; Zhang C; Lv R; Qin Q; Liu N; Yin W; Wang R; Sun Y; Wang X; Sun Y; Zhao D; Cheng M
    Eur J Med Chem; 2021 Nov; 223():113627. PubMed ID: 34171657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold.
    Wu T; Qin Q; Liu N; Zhang C; Lv R; Yin W; Sun Y; Sun Y; Wang R; Zhao D; Cheng M
    Eur J Med Chem; 2022 Feb; 230():114096. PubMed ID: 35007864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
    Wang Z; Wang J; Wang Y; Xiang S; Song X; Tu Z; Zhou Y; Zhang ZM; Zhang Z; Ding K; Lu X
    J Med Chem; 2022 Apr; 65(8):6325-6337. PubMed ID: 35426680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor.
    Ito T; Kinoshita K; Tomizawa M; Shinohara S; Nishii H; Matsushita M; Hattori K; Kohchi Y; Kohchi M; Hayase T; Watanabe F; Hasegawa K; Tanaka H; Kuramoto S; Takanashi K; Oikawa N
    J Med Chem; 2022 Sep; 65(18):12427-12444. PubMed ID: 36066182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Tropomyosin Receptor Kinase Inhibitors as New Generation Anticancer Agents: A Review.
    Panchal I; Tripathi RKP; Parmar K; Yadav MR
    Curr Top Med Chem; 2024; 24(1):3-30. PubMed ID: 38058091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational adjustment overcomes multiple drug-resistance mutants of tropomyosin receptor kinase.
    Mei LC; Zhuo LS; Xu HC; Huang W; Hao GF; Yang GF
    Eur J Med Chem; 2022 Jul; 237():114406. PubMed ID: 35486994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.
    Wang Z; Ren J; Jia K; Zhao Y; Liang L; Cheng Z; Huang F; Zhao X; Cheng J; Song S; Sheng T; Wan W; Shu Q; Wu D; Zhang J; Lu T; Chen Y; Ran T; Lu S
    Eur J Med Chem; 2022 Nov; 241():114601. PubMed ID: 35872544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.